We're making updates and relaunching soon. Get notified

Straight answers about GLP-1 medications

Plain-language guides on dosing, side effects, costs, and what to look for in a provider.

Relaunching Soon

  • Relaunching as an independent GLP-1 guide
  • Get notified when we relaunch
  • We only ask for your email
Get Started

One email to confirm. Unsubscribe anytime.

Is Compounded Semaglutide or Tirzepatide Legit? How to Tell

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy and may differ in formulation, purity, and potency.

If you are close to starting compounded semaglutide, or compounded tirzepatide, but a quiet voice keeps asking whether it is the real thing or some kind of scam, that hesitation is healthy. The short answer is that compounded semaglutide is not FDA-approved, and whether a particular source is operating lawfully depends on three things: the pharmacy, the prescription, and the form of the drug. You can check all three. Everything on this page applies to both molecules, and the tirzepatide-specific dates are in their own section below.

The short answer

Compounded semaglutide and compounded tirzepatide are real categories of medication that pharmacies prepare on a prescription. They are not scams by definition. They are also not FDA-approved, and the FDA has documented real problems with some of them.

There are three things to hold in your mind at the same time.

First, compounded semaglutide and compounded tirzepatide are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed[1]. It has not reviewed the specific product you would receive the way it reviewed the brand-name versions. That is a structural fact, not an opinion, and it should factor into your decision.

Second, the legal basis has narrowed. Compounding is allowed only under specific conditions in federal and state pharmacy law. Semaglutide and tirzepatide were on the FDA drug shortage list for a time, which gave compounders more room. The FDA has since determined both shortages were resolved, and the periods in which it allowed broader shortage-based compounding ended in 2025[2]. The details and dates are below.

Third, sources vary a great deal. The FDA has found products with labels naming pharmacies that do not exist, products using semaglutide salt forms it says have no lawful basis in compounding, and products falsely sold “for research purposes”[3]. Because no one pre-screens the specific product for you, part of the checking falls on you. The rest of this page gives you a way to do it.

Semaglutide also carries risks no matter who makes it. The FDA label for brand-name semaglutide (Wegovy injection and tablets) includes a boxed warning about thyroid C-cell tumors seen in rodents and says people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 should not use it. The label also lists serious warnings, including acute pancreatitis, gallbladder disease, low blood sugar when combined with insulin or a sulfonylurea, and kidney problems from fluid loss, and the most common side effects are gastrointestinal, such as nausea, diarrhea, vomiting, and constipation[4]. The label describes the brand-name product studied, not compounded versions.

What makes compounded semaglutide or tirzepatide legitimate

Legitimacy is not a vibe. It is a short list of concrete things you can check, and the checklist is the same whether the medication is compounded semaglutide or compounded tirzepatide. Passing these checks does not make a compounded product FDA-approved, but when several are missing, step back.

A prescription is required. The FDA advises patients to get a prescription from a licensed provider and fill it at a state-licensed pharmacy[3]. If a website lets you add either medication to a cart and check out with no medical review, that alone tells you it is not legitimate.

The pharmacy is a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility. A 503A pharmacy compounds for individual patients based on a prescription and is overseen mainly by its state board of pharmacy. A 503B outsourcing facility registers with the FDA and must follow current good manufacturing practice requirements[1]. What matters is that you can identify the pharmacy and verify its license or registration. If you want to understand the distinction, our guide on 503A versus 503B pharmacies walks through it.

The form is not a salt form. The FDA says some compounders may be using semaglutide salt forms, such as semaglutide sodium or semaglutide acetate, which are different active ingredients from the one in FDA-approved semaglutide, and that it is not aware of any lawful basis for using them in compounding[3]. Ask which form the pharmacy uses.

The ingredient source is documented. The FDA says some foreign-made GLP-1 active ingredients were made without appropriate quality controls, and it has an import alert aimed at keeping those ingredients out[3]. The pharmacy should be able to tell you where its active ingredient comes from.

A certificate of analysis is available. Some pharmacies test batches for potency, purity, and sterility and will share a certificate of analysis, or COA. Not all do, so ask for one for the batch you receive.

The pharmacy holds voluntary accreditation, or comparable quality standards. Accreditation from the Pharmacy Compounding Accreditation Board (PCAB) is voluntary, so its absence is not automatically disqualifying. It is not FDA approval.

There is ongoing provider oversight. Legitimacy is not just about the first prescription. A proper program includes a licensed provider who monitors your response, orders lab work when appropriate, and adjusts your plan over time. Medication that arrives with no follow-up and no one tracking how you are doing is a sign the medical piece is missing.

For a deeper look at how these factors affect safety specifically, see our page on whether compounded semaglutide is safe.

Red flags of an illegitimate source

It is often easier to spot what is wrong than to confirm everything that is right. Some warning signs are serious enough that any one of them should stop you. The contrast below lays out what a more transparent source looks like next to the patterns the FDA has described in its warnings[3].

Signs of a more transparent source

Requires a prescription from a licensed provider who reviews your health history. Names the compounding pharmacy and its state license or FDA outsourcing registration, which you can verify. Can tell you the form of the drug (not a salt form) and where the active ingredient comes from. Provides a certificate of analysis on request. Includes ongoing provider follow-up. Is clear that the product is not FDA-approved.

Red flags of an illegitimate source

Sells without requiring a prescription. Markets peptides as "for research purposes" or "not for human consumption" but includes dosing instructions. Ships from overseas or unverified sellers. Includes no provider follow-up. Prices that seem too good to be true. Cannot or will not name a licensed pharmacy or provide a license number. Calls the product "generic" or the same as a brand-name medication.

A few of these deserve a closer look. The FDA has warned companies that sold GLP-1 products falsely labeled “for research purposes” or “not for human consumption” directly to consumers with dosing instructions, and it urges consumers not to buy them[3]. It has also found compounded semaglutide and tirzepatide with false labels: some name pharmacies that do not exist, and some name a real licensed pharmacy that did not make the product[3]. Overseas or unverified sourcing removes the checks that come with a license you can verify. And a price far below what other sources charge, with no clear list of what is included, is worth questioning.

This is the question that trips people up, and it deserves an honest answer rather than a reassuring slogan. Neither compounded semaglutide nor compounded tirzepatide is simply “legal” or “illegal.” Whether a specific product is lawful depends on who compounded it, for whom, and from what.

Here is the plain-language version. Federal law allows compounding under specific conditions in sections 503A and 503B of the Food, Drug, and Cosmetic Act[1]. While a drug is on the FDA drug shortage list, compounders have more room to prepare copies of it. Semaglutide injection was in shortage starting in 2022, which is when compounded versions spread[2].

That situation changed. On February 21, 2025, the FDA determined that the semaglutide injection shortage was resolved. The FDA said its period of enforcement discretion for state-licensed (503A) pharmacies ended after a court decision on April 24, 2025 (the original end date was April 22, 2025), and its period for 503B outsourcing facilities ended May 22, 2025[2].

In an April 1, 2026 update, the FDA reminded compounders of the conditions that still apply. Under section 503A, a drug must be compounded for an individual patient based on a prescription, and the pharmacy may not compound, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available drug. The FDA describes a compounded drug as essentially a copy when its active pharmaceutical ingredient matches a commercially available drug’s, at a similar or easily substitutable strength, for use by the same route, unless a prescriber determines and documents that the compounded drug has a change that makes a significant difference for an identified individual patient[2]. Separately, the FDA says it is not aware of any lawful basis for compounding with semaglutide salt forms[3].

What this means for you is straightforward. Anyone who tells you compounded semaglutide or tirzepatide is “100% legal, no questions” is overselling a more complicated reality. Ask the program how it says its compounded product meets current law, and check the FDA page yourself, because the FDA may update it. For a fuller picture of how the rules shifted after supply improved, see our page on compounded GLP-1 medications after the shortage.

Is compounded tirzepatide legit?

The same checks apply. Compounded tirzepatide is not FDA-approved, and both medications are compounded under sections 503A and 503B of federal law. A prescription from a licensed provider, a pharmacy whose license or registration you can verify, a documented ingredient source, and a certificate of analysis matter for tirzepatide exactly as they do for semaglutide.

The main difference between the two molecules is the timeline. The FDA first determined the tirzepatide injection shortage was resolved on October 2, 2024, and reissued that determination on December 19, 2024. After a March 5, 2025 court decision, the FDA said its enforcement discretion period for state-licensed 503A pharmacies had ended; for 503B outsourcing facilities, it ran until March 19, 2025[2]. That is several weeks earlier than the semaglutide dates. The same 503A conditions described above, including the limits on compounding essentially copies of a commercially available drug, now apply[2].

One practical note on spotting bad actors. A seller offering tirzepatide with no prescription, or marketing it as a “research” peptide, should be treated exactly like the red flags described above. The FDA has named tirzepatide among the drugs sold falsely “for research purposes”[3].

If you are weighing tirzepatide specifically, our overview of compounded tirzepatide explains what it is and how it works, and our guide on how to get compounded tirzepatide walks through the process step by step.

How to verify a provider yourself

You do not have to take anyone’s word for it. With a few minutes and a couple of questions, you can verify the most important things on your own.

Look up the pharmacy license. Ask which compounding pharmacy will prepare your medication and for its state license number. Then search your state board of pharmacy website, which maintains a public license lookup. If the pharmacy is a 503B outsourcing facility, check the FDA’s list of registered outsourcing facilities[5]. If a seller will not name the pharmacy, that is your answer.

Ask about the form. Ask whether the semaglutide is a salt form, such as semaglutide sodium or semaglutide acetate. The FDA says it is not aware of any lawful basis for compounding with these salts[3].

Check for PCAB accreditation. You can confirm whether a pharmacy holds accreditation from the Pharmacy Compounding Accreditation Board. It is not mandatory, so its absence alone is not a dealbreaker.

Ask for the certificate of analysis. Request the COA for the batch your medication comes from. Vagueness or refusal here is a red flag.

Confirm there is a real prescription and provider review. Make sure a licensed provider reviews your health history before anything is prescribed. A proper program will tell you exactly how the provider review works.

If you want a complete checklist for evaluating a pharmacy, our guide on how to choose a safe compounding pharmacy goes step by step.

What to check before using compounded semaglutide or tirzepatide

Transformation Health is an independent guide. It does not prescribe, compound, sell, or ship medication. If you are considering compounded semaglutide or tirzepatide through any telehealth program, here is how the process should work:

A licensed provider reviews your health history. At most telehealth programs, a licensed provider reviews your health history, current medications, and goals and decides whether semaglutide or tirzepatide is clinically appropriate. A provider may decide it is not.

The prescription goes to a pharmacy you can identify. Ask the program which pharmacy prepares the medication, whether it is a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, which form of the drug it uses, and whether it provides a certificate of analysis. Confirm the license yourself.

A provider follows up. A proper program includes follow-up with a licensed provider who tracks side effects, decides on dose changes, and orders labs when needed. Ask how to reach someone with questions.

The total cost is clear before you pay. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms. To understand the full category and how compounded options are prepared, you can start with our compounded GLP-1 medications overview.

Transformation Health does not accept payment from providers. How we make money.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

Important disclosures

This content is for general education and is not medical advice. Talk with a licensed provider about your situation.

Compounded semaglutide and compounded tirzepatide are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed[1]. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy and may differ in formulation, purity, and potency. A prescription is required, and a licensed provider decides whether one is appropriate.

Regulatory status is subject to change. On February 21, 2025, the FDA determined that the semaglutide injection shortage was resolved, and on December 19, 2024, it reissued its determination that the tirzepatide injection shortage was resolved. The FDA’s shortage-based enforcement discretion periods ended in 2025. The FDA page was most recently updated April 1, 2026; check it for the current statement[2]. Availability of compounded semaglutide and tirzepatide depends on federal and state law and FDA action, and cannot be guaranteed. Nothing on this page is legal advice.

Label information describes the brand-name product studied, not compounded versions[4]. Results vary.

Wegovy is a trademark of Novo Nordisk A/S. Transformation Health is not affiliated with or endorsed by Novo Nordisk.

Citations

[1] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Content current as of 09/16/2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (Accessed 2026-10-16. Supports: compounded drugs are not FDA-approved and FDA does not verify their safety, effectiveness, or quality; sections 503A and 503B; state board oversight of 503A pharmacies; FDA registration and CGMP for outsourcing facilities.)

[2] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16. Supports: semaglutide shortage since 2022 and resolved February 21, 2025; 503A and 503B enforcement discretion end dates for semaglutide and tirzepatide; tirzepatide determinations of October 2 and December 19, 2024; April 1, 2026 reminder of 503A conditions, including the essentially-a-copy limits.)

[3] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16. Supports: salt forms and no known lawful basis; foreign-made APIs and import alert; fraudulent labels; products sold “for research purposes”; prescription and state-licensed pharmacy advice; adverse event counts as of May 31, 2026 and underreporting caveat.)

[4] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information, Boxed Warning and sections 4, 5, and 6. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf (Supports: boxed warning, contraindications, warnings and precautions, common adverse reactions.)

[5] U.S. Food and Drug Administration. “Registered Outsourcing Facilities.” Content current as of 10/13/2026. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (Accessed 2026-10-16. Supports: FDA list of registered 503B outsourcing facilities.)

Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. A licensed provider decides whether a prescription is appropriate. Compounded semaglutide and tirzepatide are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy and may differ in formulation, purity, and potency. Results vary. Availability of compounded GLP-1 medications depends on FDA policy and applicable state and federal pharmacy compounding laws, which may change. Wegovy is a trademark of Novo Nordisk A/S. Transformation Health is not affiliated with or endorsed by Novo Nordisk. Transformation Health does not accept payment from providers. How we make money.

FAQ

Frequently Asked Questions

Everything you need to know about getting started.

Still have questions?

Contact our support team
Is compounded semaglutide legal?
It depends on who compounds it and under what conditions. Federal law lets state-licensed pharmacies (section 503A) and FDA-registered outsourcing facilities (section 503B) compound drugs only when specific conditions are met. On February 21, 2025, the FDA determined that the semaglutide injection shortage was resolved, and the periods in which it allowed broader shortage-based compounding ended in 2025. As of the FDA's April 1, 2026 update, a 503A pharmacy must compound for an individual patient based on a prescription and may not regularly or in inordinate amounts compound drugs that are essentially copies of a commercially available drug, unless a prescriber documents a significant difference for that patient. The FDA also says it is not aware of any lawful basis for compounding with semaglutide salt forms. Compounded semaglutide is not FDA-approved, and the rules can change.
Is compounded semaglutide a scam?
Compounded semaglutide is a real category of medication that pharmacies prepare on prescription, not a scam by definition. But the FDA has found fraudulent products, including labels naming pharmacies that do not exist and products falsely sold "for research purposes" with dosing instructions. Check the source. A prescription from a licensed provider, a pharmacy whose license you can verify, a non-salt form, and clear answers about testing are the minimum. If any of those are missing, treat it as a red flag.
How do I know a provider is legitimate?
Ask direct questions and verify the answers. The provider should require a prescription after reviewing your health history, name the compounding pharmacy and its state license number or FDA outsourcing facility registration, tell you which form of semaglutide or tirzepatide is used, and say whether a certificate of analysis is available for your batch. You can verify a pharmacy license on your state board of pharmacy website and look up outsourcing facilities on the FDA's registered list. If a seller is vague or does not require a prescription, that is a warning sign.
Is compounded semaglutide safe?
The FDA does not review compounded drugs for safety, effectiveness, or quality, so no compounded semaglutide product has FDA-reviewed safety data. As of May 31, 2026, the FDA had received 990 adverse event reports associated with compounded semaglutide, and it says these events are likely underreported. Semaglutide itself also carries a boxed warning and other risks on its FDA label. Whether any GLP-1 medication is appropriate for you is a decision to make with a licensed provider. See our page on compounded semaglutide safety for more.
Is compounded tirzepatide legit?
The same checks apply. Compounded tirzepatide is not FDA-approved. On December 19, 2024, the FDA reissued its determination that the tirzepatide injection shortage was resolved; after a March 5, 2025 court decision, the FDA said its enforcement discretion period for 503A pharmacies had ended, and for 503B outsourcing facilities it ran until March 19, 2025. Compounding now depends on the narrower conditions in federal and state pharmacy law. Verify the pharmacy license, ask what form is used, ask for a certificate of analysis, and confirm a licensed provider reviews your health history.
Is compounded semaglutide FDA-approved?
No. Compounded drugs are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before they are marketed. Brand-name semaglutide products are FDA-approved. Compounded semaglutide is not the same as those products and may differ in formulation, purity, and potency.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

About This Site: Disclosures

Who We Are

transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. Providers and programs mentioned on this site are independent third parties.

How We Make Money

Transformation Health does not accept payment from providers.

Educational Purpose

This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Results vary. Trial results describe study participants and are not a prediction for any individual.

Compounded Medications

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy, Ozempic, Zepbound, or Mounjaro. They may differ in formulation, purity, and potency.

Trademarks

Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.